Erik Mannaert

Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia

Mariëlle Eerdekens, Ilse Van Hove, Bart Remmerie et al. · Schizophrenia Research · 2004 · 163 citations

Medicine, Pharmacokinetics, Pharmacology +10

Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta™) in patients with schizophrenia

Bo Eriksson, Per Persson, Lars Helldin et al. · The International Journal of Neuropsychopharmacology · 2005 · 118 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

A PET Study Evaluating Dopamine D₂ Receptor Occupancy for Long-Acting Injectable Risperidone

Gary Remington, David C. Mamo, Alain Labelle et al. · American Journal of Psychiatry · 2006 · 114 citations · Full text

Medicine, Pharmacology, Psychiatry +17

Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling

Loeckie De Zwart, Jan Snoeys, Jan de Jong et al. · Clinical Pharmacology & Therapeutics · 2016 · 111 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Effect of <scp>CYP</scp>3A perpetrators on ibrutinib exposure in healthy participants

Jan de Jong, Donna Skee, Joe Murphy et al. · Pharmacology Research & Perspectives · 2015 · 99 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +12